- Home
- ELVN vs GRDN Comparison
ELVN vs GRDN Comparison
Compare ELVN & GRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVN
- GRDN
- Stock Information
- Founded
- ELVN 2016
- GRDN 2004
- Country
- ELVN United States
- GRDN United States
- Employees
- ELVN N/A
- GRDN N/A
- Industry
- ELVN Biotechnology: Pharmaceutical Preparations
- GRDN Retail-Drug Stores and Proprietary Stores
- Sector
- ELVN Health Care
- GRDN Consumer Staples
- Exchange
- ELVN Nasdaq
- GRDN Nasdaq
- Market Cap
- ELVN 1.1B
- GRDN 1.4B
- IPO Year
- ELVN 2020
- GRDN 2024
- Fundamental
- Price
- ELVN $23.06
- GRDN $20.63
- Analyst Decision
- ELVN Strong Buy
- GRDN Strong Buy
- Analyst Count
- ELVN 5
- GRDN 2
- Target Price
- ELVN $37.80
- GRDN $22.50
- AVG Volume (30 Days)
- ELVN 191.8K
- GRDN 269.9K
- Earning Date
- ELVN 11-13-2024
- GRDN 02-15-2025
- Dividend Yield
- ELVN N/A
- GRDN N/A
- EPS Growth
- ELVN N/A
- GRDN N/A
- EPS
- ELVN N/A
- GRDN N/A
- Revenue
- ELVN N/A
- GRDN $1,170,907,000.00
- Revenue This Year
- ELVN N/A
- GRDN $18.05
- Revenue Next Year
- ELVN N/A
- GRDN $9.55
- P/E Ratio
- ELVN N/A
- GRDN N/A
- Revenue Growth
- ELVN N/A
- GRDN 16.86
- 52 Week Low
- ELVN $10.90
- GRDN $14.16
- 52 Week High
- ELVN $30.03
- GRDN $25.74
- Technical
- Relative Strength Index (RSI)
- ELVN 44.52
- GRDN N/A
- Support Level
- ELVN $21.55
- GRDN N/A
- Resistance Level
- ELVN $24.32
- GRDN N/A
- Average True Range (ATR)
- ELVN 1.43
- GRDN 0.00
- MACD
- ELVN 0.05
- GRDN 0.00
- Stochastic Oscillator
- ELVN 47.24
- GRDN 0.00
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.
About GRDN Guardian Pharmacy Services Inc. Class A Common Stock
Guardian Pharmacy Services Inc is a leading, highly differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. The company emphasizes high-touch, individualized clinical, drug dispensing and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as ALFs, and .BHFs.